Humana
NYSE: HUM
$381.11 ▼ -8.21  (-2.11%)
At close: Jul 27, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap45.95 Bn
P/E37.66
P/S0.44
Div. Yield0.01
ROIC (Qtr)0.02
Total Debt (Qtr)13.99 Bn
Revenue Growth (1y) (Qtr)23.47
Add ratio to table…

About

Humana Inc. headquartered in Louisville, Kentucky, operates as a health and well being company that provides insurance products and health care services through its two main platforms, Humana insurance services and CenterWell health care services. The company aims to make it easier for the people it serves to achieve their best health by delivering care and service when needed. It serves Medicare and Medicaid participants, families, individuals, military service personnel,…

Read more ↓
Sector: Healthcare Industry: Healthcare Plans CIK: 0000049071

Investment Thesis

▲ Bull case
  • Humana is strategically expanding its CenterWell ecosystem through targeted investments like the new $83 million Orlando pharmacy distribution center, which can process up to 64,000 prescriptions daily and serves both Medicare members and emerging direct-to-consumer and direct-to-employer channels. This infrastructure not only strengthens medication access for its growing Florida base—where it serves over 1.1 million Medicare Advantage members, 540,000 Medicaid beneficiaries, and 770,000 TRICARE patients—but also creates a scalable platform for higher-margin, non-insurance revenue streams. The facility’s 99.9992% dispensing accuracy rate and integration with primary care and home health services position it to drive adherence, reduce overall medical costs, and deepen customer loyalty, directly supporting the company’s goal to unlock earnings power by 2028 through vertical integration and improved health outcomes.
  • Despite near-term headwinds from Star Ratings pressure, Humana’s proactive investments in social determinants of health—exemplified by the Humana Foundation’s focus on senior mental health in Florida—are building long-term resilience in its Medicare and Medicaid populations. With one-third of Floridians projected to be over 60 by 2050 and rising rates of depression and mental health-related hospitalizations, the company’s investments in community partnerships, telehealth, caregiver support, and stigma reduction are not merely philanthropic but strategic risk mitigation. These initiatives address root causes of avoidable utilization, such as emergency department visits and inpatient admissions tied to untreated behavioral health conditions, thereby improving risk-adjusted outcomes and potentially enhancing future Star Ratings performance while lowering medical cost trends in vulnerable populations.
  • The company’s balance sheet is being structurally strengthened through sophisticated capital management, including the $1 billion issuance of junior subordinated notes in March 2026 to pre-fund 2027 maturities and over $3 billion in mitigated capital needs for 2026 via subsidiary reinsurance and legal entity optimization. These actions, combined with a disciplined capital return policy that maintains dividends while limiting buybacks to offset dilution, reflect a proactive approach to liquidity and financial flexibility that insulates the company from rating agency or regulatory stress. This foundation enables future strategic flexibility, including potential non-core asset divestitures to fund acquisitions, without compromising operational stability or growth initiatives in high-potential areas like CenterWell and Medicaid expansion.
  • Humana’s early member engagement and chronic condition identification capabilities are improving faster than anticipated, with management noting they are approximately 5% ahead of prior year’s pace on key HEDIS metrics for new members. This acceleration in gap closure—driven by enhanced data analytics, proactive outreach, and integration with the transformation office—suggests the company is not only managing risk but actively improving health outcomes in real time. Earlier identification of conditions like diabetes or hypertension allows for timely intervention, reducing complications, hospitalizations, and long-term costs, which directly supports margin expansion goals and could lead to better-than-expected medical cost trends as the year progresses, especially if sustained through Q2 and beyond.
  • The ongoing leadership transition, including Aaron Martin assuming day-to-day control of the Insurance Segment and John Barger leading Medicare Advantage operations, brings fresh operational focus without disrupting strategic continuity. With George Renaudin remaining as a strategic advisor through year-end and the company emphasizing that the transition is designed to maintain momentum on margin improvement and Star Ratings recovery, the change reflects a deepening of talent rather than a disruption. This continuity in leadership, combined with the maturity of the transformation office—which provides analytical surge and initiative tracking while holding business leaders accountable—creates a stable environment for executing complex initiatives like benefit redesign, cost optimization, and value-based care expansion ahead of the critical 2027–2028 window.
▼ Bear case
  • Humana’s path to restoring Star Ratings to the top quartile by 2028 remains uncertain and potentially overstated, as management conceded they cannot guarantee outcomes due to unknown industry thresholds, despite expressing confidence in progress. The company’s reliance on future Star improvements to offset margin pressure creates a significant dependency on a metric that is historically volatile and influenced by factors outside its direct control, such as regional performance variation and changes in CMS scoring methodology. If Star Ratings recovery lags or fails to meet expectations, the company may face sustained pressure on its Medicare Advantage reimbursement levels, forcing deeper benefit cuts or higher medical loss ratios than anticipated, which could erode member satisfaction and retention in a competitive market where rivals are also adjusting benefits.
  • The growing incidence of mental health challenges among Florida seniors—highlighted by the Humana Foundation’s own research showing over 12% diagnosed with depression and a 16% rise in mental health-related hospitalizations from 2022 to 2024—represents a mounting clinical and financial risk that current investments may not adequately address. Despite efforts to expand access through community partnerships and telehealth, Florida faces a critical shortage of geriatric-trained mental health providers, and persistent barriers like stigma, transportation limitations, and the misconception that depression is a normal part of aging limit utilization. Without meaningful improvement in diagnosis rates, treatment adherence, and outcomes, these untreated conditions could drive avoidable inpatient admissions, emergency department visits, and long-term care needs, increasing medical costs and undermining the very outcomes the company seeks to improve through its integrated care model.
  • The company’s aggressive growth in Medicaid—particularly the approximately 50,000 new lives from program launches in Michigan, Illinois, and South Carolina—may be masking underlying profitability challenges in the segment, as Medicaid typically operates at lower margins than Medicare Advantage and is subject to state-level funding volatility and eligibility restrictions. While management describes the trajectory as “on track,” the rapid expansion into new states without clear commentary on unit economics or contribution margins raises concerns that growth is being pursued at the expense of profitability, especially if these new programs require higher administrative costs, face delayed reimbursements, or encounter higher-than-expected utilization due to pent-up demand in underserved populations.
  • Humana’s increasing reliance on benefit adjustments to protect margins—acknowledged as necessary due to a widening gap between medical cost trends and federal program funding—signals a fundamental strain in its Medicare Advantage business model that may not be sustainable over the long term. The company’s admission that it must adjust benefits to remain on track for a 3% margin by 2028 implies that current federal payment structures are insufficient to cover the true cost of care for its aging, chronically ill population, and that without structural reform or significant efficiency gains, it will continually need to reduce benefits to stay profitable. This dynamic risks triggering a downward spiral where reduced benefits lead to poorer health outcomes, lower Star Ratings, and ultimately lower reimbursements, making it harder to maintain margins even with further cuts.
  • The integration of recent acquisitions like Max Health and the earlier Villages Health deal is introducing near-term earnings volatility, as management acknowledged that first-quarter results included non-recurring items such as skin substitute costs in the ACO reach program and integration expenses that are not sustainable but are currently inflating costs and distorting performance trends. While these are expected to reverse or normalize over time, the reliance on such acquisitions to drive growth in CenterWell—particularly in primary care patient growth, which reached 110,000 or 22.5% sequentially—creates execution risk if integration delays, cultural mismatches, or unforeseen liabilities arise. Furthermore, the company’s need to exclude these items to show a “more normalized” operating cost ratio throughout the year suggests that the underlying organic performance may not be as strong as the headline growth figures imply, raising questions about the true scalability and profitability of its care delivery model without M&A support.

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Healthcare Plans
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 UNH Unitedhealth Group Inc 378.05 Bn29.500.8977.92 Bn
2 CVS CVS HEALTH Corp 136.47 Bn47.011.8563.11 Bn
3 ELV Elevance Health, Inc. 81.93 Bn16.560.4531.04 Bn
4 CI Cigna Group 76.59 Bn11.720.7630.90 Bn
5 HUM Humana Inc 45.95 Bn37.660.4413.99 Bn
6 CNC Centene Corp 31.19 Bn-4.830.1716.37 Bn
7 MOH Molina Healthcare, Inc. 10.26 Bn-1,465.440.233.77 Bn
8 OSCR Oscar Health, Inc. 8.47 Bn-214.941.130.43 Bn